Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Mollee

Showing results (121-130 of 145) with videos related to

Pageof 15
Sort By:
Blood|April 8, 2026
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myelomaHans C Lee, Wouter J Plattel, Simon J Harrison, et al.
Internal Medicine Journal|August 8, 2017
Bisphosphonate guidelines for treatment and prevention of myeloma bone diseaseOi Lin Lee, Noemi Horvath, Cindy Lee, et al.
The New England Journal of Medicine|January 8, 2025
A Comparison of Peripherally Inserted Central Catheter MaterialsAmanda J Ullman, Deanne August, Tricia M Kleidon, et al.
BMJ Open|April 15, 2021
Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocolAmanda J Ullman, Deanne August, Tricia Kleidon, et al.
Haematologica|January 18, 2024
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 studySlavisa Ninkovic, Simon J Harrison, Je-Jung Lee, et al.
Internal Medicine Journal|January 12, 2017
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Constantine S Tam, Douglas Joshua, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II TrialRalf U Trappe, Daan Dierickx, Heiner Zimmermann, et al.
Transplantation|May 15, 2018
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 TrialsHeiner Zimmermann, Nina Babel, Daan Dierickx, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune InfiltrationJoshua W D Tobin, Colm Keane, Jay Gunawardana, et al.
Internal Medicine Journal|October 19, 2021
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma AustraliaKatherine Creeper, Bradley Augustson, Kieran Kusel, et al.
Pageof 15

Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
Blood|April 8, 2026
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myelomaHans C Lee, Wouter J Plattel, Simon J Harrison, et al.
Internal Medicine Journal|August 8, 2017
Bisphosphonate guidelines for treatment and prevention of myeloma bone diseaseOi Lin Lee, Noemi Horvath, Cindy Lee, et al.
The New England Journal of Medicine|January 8, 2025
A Comparison of Peripherally Inserted Central Catheter MaterialsAmanda J Ullman, Deanne August, Tricia M Kleidon, et al.
BMJ Open|April 15, 2021
Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocolAmanda J Ullman, Deanne August, Tricia Kleidon, et al.
Haematologica|January 18, 2024
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 studySlavisa Ninkovic, Simon J Harrison, Je-Jung Lee, et al.
Internal Medicine Journal|January 12, 2017
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Constantine S Tam, Douglas Joshua, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II TrialRalf U Trappe, Daan Dierickx, Heiner Zimmermann, et al.
Transplantation|May 15, 2018
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 TrialsHeiner Zimmermann, Nina Babel, Daan Dierickx, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune InfiltrationJoshua W D Tobin, Colm Keane, Jay Gunawardana, et al.
Internal Medicine Journal|October 19, 2021
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma AustraliaKatherine Creeper, Bradley Augustson, Kieran Kusel, et al.
Pageof 15